Stocktoria
Imunon, Inc. IMNN
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 1993-10-27
Imunon, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 | $500,000 | — |
| R&D expense | $7.8M | $11.6M | $11.3M | $11.7M | $10.6M | $11.3M | $13.1M | $11.9M | $13.1M | $14.6M |
| Operating income | -$14.7M | -$19.1M | -$21.0M | -$24.9M | -$21.0M | -$18.5M | -$20.6M | -$21.1M | -$18.5M | -$20.6M |
| Interest expense | — | — | $197,080 | $5.0M | $569,881 | $1.3M | — | — | — | — |
| Income tax | — | — | -$1.3M | -$1.6M | -$1.4M | -$1.8M | -$1.8M | -$10.4M | — | — |
| Net income | -$14.5M | -$18.6M | -$19.5M | -$35.9M | -$20.8M | -$21.5M | -$16.9M | -$11.9M | -$20.4M | -$22.1M |
| EPS (diluted) | $-6.83 | $-16.94 | $-2.16 | $-5.03 | — | — | — | — | — | — |
| Operating cash flow | -$13.9M | -$18.9M | -$19.0M | -$23.1M | -$16.2M | -$15.6M | -$20.3M | -$7.0M | -$16.6M | -$18.4M |
| Free cash flow | -$14.2M | -$18.9M | -$19.5M | -$23.4M | -$16.5M | -$15.6M | -$20.6M | -$7.2M | -$16.7M | -$18.4M |
| Cash & equivalents | $8.8M | $5.9M | $5.8M | $11.5M | $19.6M | $17.2M | $6.9M | $13.4M | $11.4M | $2.6M |
| Total assets | $12.3M | $9.7M | $21.9M | $44.0M | $74.0M | $37.5M | $38.3M | $46.9M | $47.5M | $30.8M |
| Total liabilities | $5.2M | $5.5M | $8.5M | $14.6M | $18.3M | $18.9M | $23.7M | $26.0M | $20.8M | $24.1M |
| Shareholders' equity | $7.1M | $4.2M | $13.4M | $29.3M | $55.8M | $18.6M | $14.6M | $20.9M | $26.7M | $6.7M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.